Rheumatology Journals

Rheumatology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Seed SM et al. – Treatment options have primarily focused on alleviating the pain often associated with this condition. Acetaminophen and nonsteroidal antiinflammatory drugs (NSAIDs) are often employed for relief of mild–to–moderate pain associated with OA. NSAIDs are typically more effective than acetaminophen; however, because of adverse effects associated with long–term use of NSAIDs, acetaminophen is considered first–line therapy. Safety concerns over traditional pharmacotherapeutic agents used in the management of OA, such as NSAIDs and opioids, have led healthcare professionals to seek other options. Trials of diseasemodulating agents that focus on preventing further damage to the joints have the potential to change how this disease state is managed. This article reviews nonpharmacologic and pharmacologic approaches to management of OA of the knee and hip.


Today in Clinical Pharmacology...keeping you current

Doxycycline for osteoarthritis of the knee or hip
Cochrane Reviews, 10/23/09

Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: Clinicopathological features of 24 patients
Journal of Rheumatology, 11/09/09

Treatment of polymyalgia rheumatica
Archives of Internal Medicine, 11/10/09

Today in Osteoarthritis...keeping you current

Doxycycline for osteoarthritis of the knee or hip
Cochrane Reviews, 10/23/09

Follow-up results of 702 patients receiving tumor necrosis factor-alpha antagonists and evaluation of risk of tuberculosis
Rheumatology International, 10/26/09

Effect of biomagnetic therapy versus physiotherapy for treatment of knee osteoarthritis: A randomized controlled trial
Journal of Rehabilitation Medicine, 11/20/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address